Scandion Oncology
K├╕benhoved
About Scandion Oncology
Scandion Oncology develops drugs that specifically target chemotherapy resistance mechanisms. Improving the outcome and quality of life for cancer patients is their mission. Drug resistance is one of the most significant challenges for successful medical treatment in oncology. Right now, half of all cancer patients fail chemotherapy. Although many cancer patients initially benefit from chemotherapy, a large proportion develop resistance to chemotherapy drugs. Few of these patients survive.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $1.7M
- Last round: Grant (Jun 2020)
- Website: scandiononcology.com
- Phone: +45 38 10 20 17
Industries & Categories
Biotechnology, Medical, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/scandion-oncology-101634 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.